Pfizer Inc. (NYSE:PFE) Shares Acquired by Bridgewealth Advisory Group LLC

Bridgewealth Advisory Group LLC increased its position in shares of Pfizer Inc. (NYSE:PFE) by 31.3% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 13,225 shares of the biopharmaceutical company’s stock after acquiring an additional 3,152 shares during the period. Bridgewealth Advisory Group LLC’s holdings in Pfizer were worth $339,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of PFE. Nordea Investment Management AB grew its stake in shares of Pfizer by 36.1% during the fourth quarter. Nordea Investment Management AB now owns 4,071,700 shares of the biopharmaceutical company’s stock worth $108,002,000 after purchasing an additional 1,080,822 shares in the last quarter. Parsons Capital Management Inc. RI increased its holdings in shares of Pfizer by 118.7% in the 4th quarter. Parsons Capital Management Inc. RI now owns 294,764 shares of the biopharmaceutical company’s stock valued at $7,820,000 after acquiring an additional 159,984 shares during the last quarter. Copley Financial Group Inc. acquired a new stake in shares of Pfizer during the 3rd quarter worth about $577,000. Mcdonald Partners LLC lifted its stake in Pfizer by 9.9% during the fourth quarter. Mcdonald Partners LLC now owns 110,296 shares of the biopharmaceutical company’s stock worth $2,926,000 after purchasing an additional 9,963 shares during the last quarter. Finally, Merit Financial Group LLC increased its stake in Pfizer by 60.8% in the fourth quarter. Merit Financial Group LLC now owns 127,967 shares of the biopharmaceutical company’s stock valued at $3,395,000 after purchasing an additional 48,397 shares during the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts recently commented on PFE shares. Citigroup reaffirmed a “neutral” rating on shares of Pfizer in a research report on Thursday, March 27th. Guggenheim reissued a “buy” rating on shares of Pfizer in a report on Tuesday, March 18th. Hsbc Global Res upgraded Pfizer to a “strong-buy” rating in a research note on Monday, March 10th. Cantor Fitzgerald initiated coverage on Pfizer in a research report on Tuesday, April 22nd. They set a “neutral” rating and a $24.00 price target on the stock. Finally, UBS Group lowered their target price on shares of Pfizer from $28.00 to $24.00 and set a “neutral” rating on the stock in a research report on Tuesday, April 8th. One research analyst has rated the stock with a sell rating, nine have given a hold rating, five have assigned a buy rating and three have assigned a strong buy rating to the company’s stock. According to MarketBeat, Pfizer presently has an average rating of “Moderate Buy” and a consensus price target of $29.57.

Insider Buying and Selling at Pfizer

In other news, Director Ronald E. Blaylock bought 19,457 shares of the business’s stock in a transaction that occurred on Thursday, February 13th. The shares were acquired at an average cost of $25.65 per share, with a total value of $499,072.05. Following the transaction, the director now owns 27,707 shares of the company’s stock, valued at $710,684.55. This represents a 235.84 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. 0.06% of the stock is owned by company insiders.

Pfizer Price Performance

Pfizer stock opened at $23.80 on Wednesday. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The firm’s 50-day simple moving average is $24.48 and its 200 day simple moving average is $25.86. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $31.54. The firm has a market capitalization of $134.98 billion, a PE ratio of 16.88, a P/E/G ratio of 0.64 and a beta of 0.67.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, beating analysts’ consensus estimates of $0.67 by $0.25. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm had revenue of $13.72 billion for the quarter, compared to analysts’ expectations of $14.43 billion. During the same quarter in the prior year, the firm earned $0.82 EPS. Pfizer’s quarterly revenue was down 7.8% on a year-over-year basis. On average, equities research analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 13th. Stockholders of record on Friday, May 9th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 7.23%. The ex-dividend date of this dividend is Friday, May 9th. Pfizer’s dividend payout ratio (DPR) is 121.99%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.